Table 1.

Patient demographic data and clinical characteristics at baseline (before start of conditioning regimen) and around day 100 after hematopoietic cell transplantation

CharacteristicBaseline (n=50)Approximately 100 days (n=35)
Age at HCT (yr)
 18–399 (18)6 (17)
 40–5926 (52)18 (52)
 ≥6015 (30)11 (31)
 Median5555
 Range23–72.323–69
Sex
 Men38 (76)28 (80)
 Women12 (24)7 (20)
Race
 Caucasian46 (92)33 (94)
 Hispanics1 (2)1 (3)
 Other2 (4)1 (3)
 Not available1 (2)0 (0)
Diagnosis for HCT
 AML15 (30)8 (23)
 ALL6 (12)5 (14)
 CLL5 (10)5 (14)
 CML4 (8)1 (3)
 MDS6 (12)6 (16)
 NHL6 (12)3 (9)
 MM2 (4)2 (6)
 Myelofibrosis3 (6)2 (6)
 Other3 (6)3 (9)
Donor type
 Allogeneic (related matched)11 (22)11 (31)
 Allogeneic (related mismatched)4 (8)3 (9)
 Autologous6 (12)4 (11)
 Unrelated donor24 (48)17 (49)
 Not transplanted5 (10)0 (0)
Conditioning regimen
 Reduced intensity regimens12 (24)10 (29)
 Myeloablative
  CY/TBI 12–13.5 cGy9 (18)5 (14)
  BU/CY only12 (24)7 (20)
 Other myeloablative regimens17 (34)13 (37)
Mean body mass index (kg/m2)29.6±5.427.2±4.3
Mean weight (kg)88±22.282±18.0
Mean BSA2.02±0.31.96±0.3
Hypertensive and on medication
 Yes5 (10)24 (69)
On steroid
 Yes3 (6)19 (54)
On sulfamethoxazole/trimethoprim
 Yes22 (44)22 (63)
Diabetes
 Yes0 (0)5 (14)
 No50 (100)30 (86)
ACR (mg/g creatinine)
 <3015 (43)
 30–2998 (23)
 ≥3004 (11)
 Not available8 (23)
aGVHD grade
 0 or I8 (23)
 II18 (51)
 III or IV2 (6)
 Not graded5 (14)
 Autologous2 (6)
cGVHD
 Yes15 (43)
 No13 (37)
 Not available7 (20)
  • HCT, hematopoietic cell transplantation; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkins lymphoma; MM, multiple myeloma; CY, cytoxan; TBI, total body irradiation; BU, busulfan; BSA, body surface area; ACR, albumin-to-creatinine ratio; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.